Table 1 Demographic and clinical characteristics of 83 study participants, and median (IQR) change in bilirubin concentrations over the first 12Â weeks of ATV treatment
From: Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir
|  | N (%) | Median (IQR) change in bilirubin (μmol/L) | P- value |
|---|---|---|---|
Gender | Â | Â | Â |
 Male | 46 (55.4) | 15 (4, 20) | 0.23 |
 Female | 37 (44.6) | 17 (4, 32) |  |
Age (years) | Â | Â | Â |
 Median (IQR) | 33 (29, 40) |  |  |
  ≤ 30 | 27 (32.5) | 16 (3, 31) |  |
 31-40 | 38 (45.8) | 15 (5, 21) |  |
  > 40 | 18 (21.7) | 17.5 (1, 23) | 0.75 |
Ethnicity | Â | Â | Â |
 Caucasian | 61 (73.5) | 13 (4, 21) |  |
 Non-caucasian | 22 (26.5) | 21 (13, 32) | 0.05 |
Acquisition risk | Â | Â | Â |
 IVDU | 51 (61.5) | 13 (3, 20) |  |
 Non-IVDU | 32 (38.5) | 21 (12, 30) | 0.01 |
AIDS | Â | Â | Â |
 Yes | 53 (63.9) | 15 (4, 22) |  |
 No | 30 (36.1) | 17 (7, 21) | 0.85 |
Methadone use | Â | Â | Â |
 Yes | 37 (44.6) | 7 (1, 19) | 0.001 |
 No | 46 (55.4) | 20 (13, 26) |  |
Hepatitis C antibody | Â | Â | Â |
 Positive | 46 (60.5) | 10 (3, 20) |  |
 Negative | 37 (39.5) | 21 (13, 31) | 0.01 |
Hepatitis C PCR | Â | Â | Â |
 Positive | 36 (43.4) | 10 (3, 20) |  |
 Negative | 47 (56.6) | 20 (7, 29) | 0.02 |
Hepatitis B sAG | Â | Â | Â |
 Positive | 4 (4.8) | 17 (13, 27.5) |  |
 Negative | 73 (90.0) | 17 (4, 22) | 0.55 |
Treatment status at baseline | Â | Â | Â |
 Experienced | 50 (60.2) | 17 (4, 22) | 0.21 |
 Naïve | 32 (38.6) | 12 (2.5, 21) |  |
HIV RNA <50 copies/ml at baseline | Â | Â | Â |
 No | 68 (81.9) | 14 (3.5, 21.5) |  |
 Yes | 15 (18.1) | 18 (13, 22) | 0.31 |
NRTI | Â | Â | Â |
 TDF | 42 (42.2) | 11 (2, 20) |  |
 Non-TDF | 41 (50.6) | 18 (19, 24) | 0.02 |